NVS•Novartis ended a mid-stage study testing Fabhalta for lupus nephritis, citing strategic considerations and saying the decision was not driven by interim efficacy or safety findings.
Novartis terminated the study after completing its first part. It was testing whether oral Fabhalta was safe and effective for lupus nephritis when added to standard medical care.
The company said other studies of Fabhalta will continue as planned. Investigators have been notified and are discussing next steps with participants. Fabhalta was approved in 2023 for PNH and has since been approved for IgA nephropathy and C3 glomerulopathy.
